Sara Hurvitz MD, Kelly McCann

HER2-Positive Breast Cancer (eBook, ePUB)

• Format: ePub

Produktbeschreibung

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier HealthScience EN
• Seitenzahl: 264
• Erscheinungstermin: 26. Juli 2018
• Englisch
• ISBN-13: 9780323581233
• Artikelnr.: 53470768

Inhaltsangabe

Background/testing

1. The HER2 alteration in breast cancer

2. HER2 testing in the era of changing guidelines

Advanced Disease

3. Optimal first-line treatment of HER2+ advanced disease

4. Second line therapy and beyond

5. HER2+ CNS metastases

Therapeutics

6. Neoadjuvant therapy

7. Adjuvant therapy

8. Outcomes based on HR status in early stage disease

9. De-escalation of therapy for small tumor

Toxicity considerations

10. Cardiac toxicity of HER2-targeted regimens

11. Non-cardiac toxicity of HER2-targeted therapy

Therapies on the horizon

12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)

13. Harnessing the immune system in HER2+ disease

14. Biosimilars